CDR2 and paraneoplastic neurologic syndrome: Indeed, Small and colleagues showed that tumor cells from all 25 PCD patients with anti-Yo antibodies exhibited (likely somatic) mutations and/or gains in CDR2 and/or CDR2L genes, leading to higher protein expression and/or expression of proteins with missense mutations.